

Cellnovo to Present at the 2015 Canaccord Genuity Medical Technology & Diagnostics Forum

Paris, France, November 19, 2015 – Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first connected all-in-one diabetes management system, today announces that Sophie Baratte, Chief Executive Officer of Cellnovo, is scheduled to present at the Canaccord Genuity Medical Technology & Diagnostics Forum today at 1:00 pm EDT. The conference will be held at the Westin Grand Central in New York, NY.

A live webcast of Cellnovo’s presentation can be accessed via the following link: <http://wsw.com/webcast/canaccord20/clnv.pa>. An archived audio of the discussion will also be available on Cellnovo’s website for 90 days.

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

For further information please visit www.cellnovo.com

Contact

Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Emmanuel Huynh
+ 33 1 44 71 00 16

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu

Consilium Strategic Communications

Media Relations in United Kingdom
Amber Fennell, Chris Gardner, Laura
Thornton
+44 20 3709 5700
cellnovo@consilium.com

Cellnovo is listed on Euronext,
Compartment C
ISIN: FR0012633360 – Ticker:
CLNV

